Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-DOTA-Ahx-(D-Lys6)-LHRH
- Development stage
- Preclinical
- Lead developer
- Centro Uruguayo de Imagenología Molecular
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
68Ga-DOTA-Ahx-(D-Lys6)-LHRH is a gallium-68 labeled luteinizing hormone-releasing hormone (LHRH) peptide analogue conjugated to the chelator DOTA via an aminohexanoic acid (Ahx) linker. It is designed as a diagnostic radiopharmaceutical for positron emission tomography (PET) imaging of cancers that overexpress the LHRH receptor (also known as gonadotropin-releasing hormone receptor, GNRHR), such as prostate cancer and breast cancer. The targeting peptide moiety, [D-Lys6]-LHRH, binds with high affinity and specificity to LHRH receptors on tumor cells, allowing for precise localization and visualization of LHRH receptor-expressing malignancies. The agent is being developed by researchers at the Universidad de la República and the Centro Uruguayo de Imagenología Molecular (CUDIM) in Uruguay.
- Other names
- [68Ga]68Ga-DOTA-Ahx-(D-Lys6)-LHRH[68Ga]Ga-DOTA-Ahx-(D-Lys(6))-LHRH[68Ga]Ga-DOTA-Ahx-(D-Lys6)-GnRH1[68Ga]Ga-DOTA-Ahx-(D-Lys6)-LHRH[68Ga]Ga-DOTA-Ahx-(D-Lys6)LHRH[68Ga]Ga-DOTA-Ahx-(DLys6)-LHRH68Ga-DOTA-Ahx-(D-Lys(6)-GnRH1)68Ga-DOTA-Ahx-(D-Lys6)-GnRH168Ga-DOTA-Ahx-(DLys6)-LHRH
02
Targets
GnRHR (Gonadotropin-releasing hormone receptor)
Beyond the preview
Go deeper on 68Ga-DOTA-Ahx-(D-Lys6)-LHRH.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68Ga-DOTA-Ahx-(D-Lys6)-LHRH.